

Alastair J O'brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6782975/publications.pdf>

Version: 2024-02-01

44
papers

2,097
citations

394421

19
h-index

289244

40
g-index

45
all docs

45
docs citations

45
times ranked

2811
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Albumin Infusions Do Not Improve Systemic Inflammation or Cardiovascular Function in Decompensated Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00476.	2.5	7
2	Long-term albumin treatment in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2022, 76, 1306-1317.	3.7	16
3	Guidelines on the management of ascites in cirrhosis. <i>Gut</i> , 2021, 70, 9-29.	12.1	280
4	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19. , 2021, 221, 107745.		8
5	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 808-817.	27.0	181
6	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway. <i>JHEP Reports</i> , 2021, 3, 100332.	4.9	6
7	Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial. <i>American Journal of Gastroenterology</i> , 2021, 116, 2292-2295.	0.4	12
8	Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1207-1215.e6.	4.4	12
9	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	2.4	8
10	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	12.1	190
11	Impaired LXR β Phosphorylation Attenuates Progression of Fatty Liver Disease. <i>Cell Reports</i> , 2019, 26, 984-995.e6.	6.4	46
12	Effectiveness of intravenous albumin therapy to prevent spontaneous bacterial peritonitis, renal dysfunction and death in adults with cirrhosis: a protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025664.	1.9	1
13	Development and validation of a prediction model to estimate the risk of liver cirrhosis in primary care patients with abnormal liver blood test results: protocol for an electronic health record study in Clinical Practice Research Datalink. <i>Diagnostic and Prognostic Research</i> , 2019, 3, 10.	1.8	11
14	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal Microbiota Transplantation in cirrhosis: study protocol for a single-blinded trial. <i>BMJ Open</i> , 2019, 9, e023518.	1.9	27
15	Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e031070.	1.9	45
16	Diagnosis and management of ascites and hepatorenal syndrome (acute kidney injury) in cirrhosis. <i>Medicine</i> , 2019, 47, 828-832.	0.4	0
17	Con: The Unclear Benefit of Albumin. <i>Liver Transplantation</i> , 2019, 25, 135-139.	2.4	6
18	Effectiveness of pneumococcal and influenza vaccines to prevent serious health complications in adults with chronic liver disease: a protocol for a systematic review. <i>BMJ Open</i> , 2018, 8, e018223.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 738-747.e7.	4.4	47
20	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 748-755.e6.	4.4	19
21	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e023754.	1.9	22
22	MACHT " Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list. <i>Journal of Hepatology</i> , 2018, 69, 1217-1218.	3.7	6
23	Monocyte and Neutrophil Isolation, Migration, and Phagocytosis Assays. <i>Current Protocols in Immunology</i> , 2018, 122, e53.	3.6	2
24	Antimicrobial resistance in liver disease: better diagnostics are needed. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 151-153.	8.1	5
25	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. <i>Gut</i> , 2017, 66, 519-529.	12.1	54
26	A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0165502.	2.5	7
27	Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. <i>Annals of Surgery</i> , 2016, 263, 1028-1037.	4.2	41
28	Is human albumin solution really the best resuscitation fluid for patients with advanced cirrhosis?. <i>Gut</i> , 2016, 65, 1392-1393.	12.1	0
29	Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences. <i>Liver International</i> , 2016, 36, 837-846.	3.9	20
30	The potential danger of empiric antimicrobial therapy for nosocomial SBP. <i>Hepatology</i> , 2016, 64, 2267-2268.	7.3	2
31	Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1699-1701.	27.0	30
32	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial. <i>BMJ Open</i> , 2016, 6, e010132.	1.9	7
33	Lipid mediators in immune dysfunction after severe inflammation. <i>Trends in Immunology</i> , 2014, 35, 12-21.	6.8	78
34	Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. <i>Nature Medicine</i> , 2014, 20, 518-523.	30.7	240
35	Pathways mediating resolution of inflammation: when enough is too much. <i>Journal of Pathology</i> , 2013, 231, 8-20.	4.5	61
36	Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. <i>Intensive Care Medicine</i> , 2012, 38, 991-1000.	8.2	87

#	ARTICLE	IF	CITATIONS
37	BK Large Conductance Ca ²⁺ -Activated K ⁺ Channel-Deficient Mice are not Resistant to Hypotension and Display Reduced Survival Benefit Following Polymicrobial Sepsis. <i>Shock</i> , 2011, 35, 485-491.	2.1	13
38	VARIABLE EFFECTS OF INHIBITING iNOS AND CLOSING THE VASCULAR ATP-SENSITIVE POTASSIUM CHANNEL (VIA ITS PORE-FORMING AND SULFONYLUREA RECEPTOR SUBUNITS) IN ENDOTOXIC SHOCK. <i>Shock</i> , 2009, 31, 535-541.	2.1	12
39	Rapid diagnosis of Wilson disease in acute liver failure: No more waiting for the ceruloplasmin level?. <i>Hepatology</i> , 2008, 48, 1030-1032.	7.3	16
40	Nutrition in End-Stage Liver Disease: Principles and Practice. <i>Gastroenterology</i> , 2008, 134, 1729-1740.	1.3	134
41	Vasopressin in Septic Shock – A Step Forward or Just Another Vasopressor?. <i>Journal of the Intensive Care Society</i> , 2006, 7, 38-41.	2.2	0
42	The pore-forming subunit of the KATP channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. <i>British Journal of Pharmacology</i> , 2005, 144, 367-375.	5.4	32
43	Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i> , The, 2005, 365, 1873-1875.	13.7	28
44	Terlipressin for norepinephrine-resistant septic shock. <i>Lancet</i> , The, 2002, 359, 1209-1210.	13.7	274